This treatment disrupts the ring barrier structure of MMP19+ TAMs, facilitating the infiltration of CD8+ T cells into the tumor interior, and consequently enhances the sensitivity of LC-BoM to immunotherapy (Figure 9J). The gene discussed is CD8A; the disease is neoplasm.